András Matolcsy

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: THE JOURNAL OF PATHOLOGY: CLINICAL RESEARCH. 2024;10(1):e351
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation
Laszlo T; Kotmayer L; Fesus V; Hegyi L; Grof S; Nagy A; Kajtar B; Balogh A; Weisinger J; Masszi T; Nagy Z; Farkas P; Demeter J; Istenes I; Sazsz R; Gergely L; Sulak A; Borbenyi Z; Levai D; Schneider T; Pettendi P; Bodai E; Szerafin L; Rejto L; Batai A; Domotor MA; Santa H; Plander M; Szendrei T; Hamed A; Lazar Z; Pauker Z; Radvanyi G; Kiss A; Korosmezey G; Jakucs J; Dombi PJ; Simon Z; Klucsik Z; Gurzo M; Tiboly M; Vidra T; Ilonczai P; Bors A; Andrikovics H; Egyed M; Szekely T; Masszi A; Alpar D; Matolcsy A; Bodor C
Article: JOURNAL OF INTERNAL MEDICINE. 2023;294(3):295-313
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Nagy A; Batai B; Kiss L; Grof S; Kiraly PA; Jona A; Demeter J; Santa H; Batai A; Pettendi P; Szendrei T; Plander M; Koeroesmezey G; Alizadeh H; Kajtar B; Mehes G; Krenacs L; Timar B; Csomor J; Toth E; Schneider T; Mikala G; Matolcsy A; Alpar D; Masszi A; Bodor C
Article: BRITISH JOURNAL OF CANCER. 2023;129(3):455-465
PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia
Bedics G; Egyed B; Kotmayer L; Benard-Slagter A; de Groot K; Beko A; Hegyi LL; Batai B; Krizsan S; Krivan G; Erdelyi DJ; Mueller J; Haltrich I; Kajtar B; Pajor L; Vojcek A; Ottoffy G; Ujfalusi A; Szegedi I; Tiszlavicz LG; Bartyik K; Csanadi K; Peter G; Simon R; Hauser P; Kelemen A; Sebestyen E; Jakab Z; Matolcsy A; Kiss C; Kovacs G; Savola S; Bodor C; Alpar D
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2023;25(8):555-568
Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.
Krizsán S; Péterffy B; Egyed B; Nagy T; Sebestyén E; Hegyi LL; Jakab Z; Erdélyi DJ; Müller J; Péter G; Csanádi K; Kállay K; Kriván G; Barna G; Bedics G; Haltrich I; Ottóffy G; Csernus K; Vojcek Á; Tiszlavicz LG; Gábor KM; Kelemen Á; Hauser P; Gaál Z; Szegedi I; Ujfalusi A; Kajtár B; Kiss C; Matolcsy A; Tímár B; Kovács G; Alpár D; Bödör C
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023;24(6):5802
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
Kotmayer L; Laszlo T; Mikala G; Kiss R; Levay L; Hegyi LL; Grof S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulak A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szasz R; Bodor C; Alpar D
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2022;24(3):224-240
Distinct miRNA Expression Signatures of Primary and Secondary Central Nervous System Lymphomas
Sebestyen E; Nagy A; Marosvari D; Rajnai H; Kajtar B; Deak B; Matolcsy A; Brandner S; Storhoff J; Chen N; Bago AG; Bodor C; Reiniger L
Article: PATHOLOGY. 2022;54(1):95-103
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax
Gango A; Kiss R; Farkas P; Hanna E; Demeter J; Deak B; Levai D; Kotmayer L; Alpar D; Matolcsy A; Bodor C; Matrai Z; Timar B
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2022;101(2):159-166
Limitations of VS38c labeling in the detection of plasma cell myeloma by flow cytometry.
Czeti Á; Szalóki G; Varga G; Szita VR; Komlósi ZI; Takács F; Márk Á; Timár B; Matolcsy A; Barna G
Article: HEMATOLOGICAL ONCOLOGY. 2021;39(4):513-520
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;194(2):355-364
Screening and monitoring of the BTK^C481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy
Bodor C; Kotmayer L; Laszlo T; Takacs F; Barna G; Kiss R; Sebestyen E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtar B; Kohl Z; Szasz R; Gergely L; Gurbity Palfi T; Sulak A; Kollar B; Egyed M; Plander M; Rejto L; Szerafin L; Ilonczai P; Tamaska P; Pettendi P; Levai D; Schneider T; Sebestyen A; Csermely P; Matolcsy A; Matrai Z; Alpar D
Article: ORVOSI HETILAP. 2021;162(13):488-496
[Graft survival using cadaver and multiorgan donors between 2008 and 2017 in our department].
Kovács K; Szentmáry N; Pluzsik MT; Langenbucher A; Kiss H; Füst Á; Kriskó D; Rácz G; Matolcsy A; Nagy ZZ
Article: PATHOLOGY AND ONCOLOGY RESEARCH. 2020;26(4):2765-2772
Grade I, II and III Follicular Lymphomas Express Ig V_H Genes with Different Patterns of Somatic Mutation
Csernus B; Timar B; Fulop Z; Matolcsy A
Article: GENES. 2020;11(7):E785-785
Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma
Nagy A; Batai B; Balogh A; Illes S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpar D; Masszi T; Masszi A; Bodor C
Article: MODERN PATHOLOGY. 2020;33(5):812-824
Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia.
Kiss R; Gángó A; Benard-Slagter A; Egyed B; Haltrich I; Hegyi L; de Groot K; Király PA; Krizsán S; Kajtár B; Pikó H; Pajor L; Vojcek Á; Matolcsy A; Kovács G; Szuhai K; Savola S; Bödör C; Alpár D
Article: JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 2020;79(2):176-183
Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;146(1):85-93
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
Article: PATHOLOGY. 2019;51(3):301-307
Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Article: PATHOLOGY AND ONCOLOGY RESEARCH. 2019;25(2):647-652
The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells.
Takács F; Tolnai-Kriston C; Hernádfői M; Szabó O; Szalóki G; Szepesi Á; Czeti Á; Matolcsy A; Barna G
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2018;20(6):777-788
High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma.
Kosztolányi S; Kiss R; Atanesyan L; Gángó A; de Groot K; Steenkamer M; Jáksó P; Matolcsy A; Kajtár B; Pajor L; Szuhai K; Savola S; Bödör C; Alpár D
Article: ANNALS OF HEMATOLOGY. 2018;97(11):2145-2152
In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
Kriston C; Plander M; Márk Á; Sebestyén A; Bugyik E; Matolcsy A; Barna G
Article: EXPERIMENTAL AND MOLECULAR PATHOLOGY. 2018;105(2):161-165
EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes.
Szurián K; Csala I; Marosvári D; Rajnai H; Dezső K; Bödör C; Piurkó V; Matolcsy A; Reiniger L
Article: VIRCHOWS ARCHIV. 2018;473(4):453-462
Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
Article: LEUKEMIA RESEARCH. 2018;65:42-48
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
Article: PATHOLOGY AND ONCOLOGY RESEARCH. 2018;24(1):83-88
Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
Article: HEMATOLOGICAL ONCOLOGY. 2017;35(4):741-745
The effect of microenvironmental factors on the development of myeloma cells.
Márk Á; Varga G; Timár B; Kriston C; Szabó O; Deák L; Matolcsy A; Barna G
Article: EUROPEAN JOURNAL OF HUMAN GENETICS. 2017;25(8):1020-1024
Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.
Tawana K; Wang J; Király PA; Kállay K; Benyó G; Zombori M; Csomor J; Al Seraihi A; Rio-Machin A; Matolcsy A; Chelala C; Cavenagh J; Fitzgibbon J; Bödör C
Article: LEUKEMIA RESEARCH. 2017;58:39-42
Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
Szurián K; Csala I; Piurkó V; Deák L; Matolcsy A; Reiniger L
Article: HEMATOLOGICAL ONCOLOGY. 2017;35(1):58-63
Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL.
Kriston C; Bödör C; Szenthe K; Bánáti F; Bánkuti B; Csernus B; Reiniger L; Csomor J; Matolcsy A; Barna G
Article: ORVOSI HETILAP. 2017;158(6):220-228
[TP53 mutation analysis in chronic lymphocytic leukaemia].
Fésüs V; Marosvári D; Kajtár B; Király PA; Demeter J; Gurbity Pálfi T; Egyed M; Plander M; Farkas P; Mátrai Z; Matolcsy A; Bödör C
Article: ONCOTARGET. 2016;7(46):74686-74700
Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Bjornstedt M
Article: HAEMATOLOGICA. 2014;99(6):1041-1049
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Goehring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellstrom-Lindberg E
Visa fler

Alla övriga publikationer

Meeting abstract: BLOOD. 2019;134:1474
Comprehensive Profiling of Disease-Relevant Copy Number Aberrations Improves Risk Assessment and Unveils the Clonal Origin of Relapse in Pediatric Acute Lymphoblastic Leukemia
Alpar D; Kiss R; Gango A; Benard-Slagter A; Egyed B; Haltrich I; Hegyi L; de Groot K; Kiraly PA; Krizsan S; Kajtar B; Piko H; Pajor L; Vojcek A; Matolcsy A; Kovacs G; Szuhai K; Savola S; Bodor C
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19:s279
Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib
Gango A; Alpar D; Galik B; Marosvari D; Kiss R; Fesus V; Aczel D; Nagy N; Nagy A; Krizsan S; Reiniger L; Farkas P; Kozma A; Adam E; Tasnady S; Reti M; Matolcsy A; Gyenesei A; Matrai Z; Bodor C
Editorial comment: HAEMATOLOGICA. 2019;104(1):e38-e41
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Kiss R; Alpár D; Gángó A; Nagy N; Eyupoglu E; Aczél D; Matolcsy A; Csomor J; Mátrai Z; Bödör C
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2018;101:s11
1p36 deletion is associated with TNFRSF14 mutations in primary cutaneous follicle center lymphoma
Batai B; Gango A; Varga M; Kapczar D; Papp G; Marschalko M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bodor C; Szepesi A

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI